TCT、HPV和阴道镜下宫颈组织活检对宫颈病变的诊断价值

Abstract
Figure/Table
References (20)
Related Citation (8)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the diagnosis meaning of thinprep liquid-based cytology test（TCT），human papillomavirus（HPV）test and cervical biopsy under colposcope for cervical lesions. Methods TCT screening patients with abnormal，among 5137 people，from December 2013 to August 2015 of outpatient and physical examination in our hospital were tested with HPV test，colposcopy examination and cervical tissues were got for biopsy.The meaning of three methods for diagnosis cervical lesions was compared on the standard of histopathology. Results①The positive detection rate of cervical biopsy was obvious higher than the positive detection rate of TCT and HPV（P＜0.01）.②The incidence of cervical intraepithelial neoplasia in HPV positive group was significantly higher than that in negative group（P＜0.01），and the degree of cervical lesions in HPV positive group was significantly higher than that in negative group（P＜0.05）. ③With the increased of cervical cytological inspection results degree，the incidence rate of HPV infection increased and the number of pathological diagnosis as cervical intraepithelial neoplasia increased（P＜0.05）.The positive rate of TCT，HPV combined with cervical biopsy under colposcope was 100.00%. Conclusion TCT，HPV test and colposcopy examination and biopsy are assist measure for diagnosis cervical lesions.All of the three have advantages and disadvantages，and integrated use of them can increase the detection rate of cervical lesions.

Key words： Cervical intraepithelial neoplasia Liquid based cytology Human papillomavirus Colposcopy Cervical biopsy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SU Qing
	PAN Zhuo
	HU Chang-e
	SU Jing-jing

Cite this article:

SU Qing,PAN Zhuo,HU Chang-e, et al. ExPloring the aPPlication of TCT，HPV and cervical bioPsy under colPoscoPe for screening cervical lesions[J]. 中国当代医药, 2016, 23(11): 84-87.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I11/84

［1］	Arbyn M，Castellsagué X，de Sanjosé S，et al.Worldwide burden of cervical cancer in 2008［J］.Ann Oncol，2011，22（12）：2675-2686.
［2］	Forouzanfar MH，Foreman KJ，Delossantos AM，et al.Breast and cervical cancer in 187 countries between 1980 and 2010：a systematic analysis［J］.Lancet，2011，378（9801）：1461-1481.
［3］	Wright TC Jr，Massad LS，Dunton CJ，et al.2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ［J］.Am J Obstet Gynecol，2007，197（4）：340-345.
［4］	李倩.宫颈上皮内瘤变锥切术后复发高危因素研究进展［J］.中国实用妇科与产科杂志，2011，27（3）：220-222.
［5］	zur Hausen H.Papillomaviruses in the causation of human cancers-a brief historical account［J］.Virology，2009，384（2）：260-265.
［6］	Alonso I，Torné A，Puig-Tintoré LM，et al.Pre-and postconization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN2-3［J］.Gynecol Oncol，2006，103（2）：631-636.
［7］	Rey-Ares L，Ciapponi A，Pichon-Riviere A.Efficacy and safety of human papilloma virus accine in cervical cancer prevention：systematic review and meta -analysis［J］.Arch Argent Pediatr，2012，110（6）：483-489.
［8］	Ramanakumar AV，Goncalves O，Richardson H，et al.Human papillomavirus（HPV）types 16，18，31，45 DNA loads and HPV-16 integration in persistent and transient infections in young women［J］.BMC infect Dis，2010，10（1）：326.
［9］	de Villiers EM.Human pathogenic papillomavirus types：an upgrade［J］.Curr Top Microbiol Immunol，1994，（186）：1-12.
［10］	Stany MP，Bidus MA，Reed EJ，et al.The prevalence of HR-HPV DNA in ASC-US Papsmears：a military population study［J］.Gynecol Oncol，2006，101（1）：82-85.
［11］	Guo M，Gong Y，Wang J，et al.The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaouresults［J］.Cancer Cytopathol， 2013，121（2）：79-85.
［12］	Ronco G，Dillner J，Elfstrom KM，et al.Efficacy of HPV-based screening for prevention of invasive cervical cancer：follow -up of four European randomised controlled trials［J］.Lancet，2014，383（9916）：524-532.
［13］	Dunne EF，Klein NP，Naleway AL，et al.Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system：baseline assessment to measure HPV vaccine impact［J］.Cancer Causes Control，2013，24（2）：403-407.
［14］	Badaracco G，Savarese A，Micheli A，et al.Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer［J］.Oncol Rep，2010，23（4）：1093-1099.
［15］	Brandsma JL，Shlyankevich M，Zhang L，et al.Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection［J］.J Virol，2004，78（1）：116-123.
［16］	Schwarz E，Freese UK，Gissmann L，et al.Structure and transcription of human papillomavirus sequences in cervical carcinoma cells［J］.Nature，1985，314（6006）：111-114.
［17］	Oh KJ，Kalinina A，Bagchi S.Destabilization of Rb by human papillomavirus E7 is cell cycle dependent：E2-25K is involved in the proteolysis［J］.Virology，2010，396（1）：118-124.
［18］	Gammoh N，Isaacson E，Tomai'c V，et al.Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2［J］.Oncogene，2009，28（23）：2299-2304.
［19］	Huh K，Zhou X，Hayakawa H，et al.Human papillomavirus type16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex，which contributes to degradation of the retinoblastoma tumor suppressor［J］.J Virol，2007，81 （18）：9737-9747.
［20］	Jeon S，Allen -Hoffmann BL，Lambert PF.Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells［J］.J Virol，1995，69（5）：2989-2997.